These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29574039)

  • 21. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer.
    Sundar R; Rha SY; Yamaue H; Katsuda M; Kono K; Kim HS; Kim C; Mimura K; Kua LF; Yong WP
    BMC Cancer; 2018 Mar; 18(1):332. PubMed ID: 29587677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE
    Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
    Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
    Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
    Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
    Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
    Speetjens FM; Kuppen PJ; Welters MJ; Essahsah F; Voet van den Brink AM; Lantrua MG; Valentijn AR; Oostendorp J; Fathers LM; Nijman HW; Drijfhout JW; van de Velde CJ; Melief CJ; van der Burg SH
    Clin Cancer Res; 2009 Feb; 15(3):1086-95. PubMed ID: 19188184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination.
    Chen Q; Jackson H; Shackleton M; Parente P; Hopkins W; Sturrock S; MacGregor D; Maraskovsky E; Tai TY; Dimopoulos N; Masterman KA; Luke T; Davis ID; Chen W; Cebon J
    Cancer Immun; 2005 Mar; 5():5. PubMed ID: 15755075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients.
    Waki K; Kawano K; Tsuda N; Komatsu N; Yamada A
    Cancer Sci; 2020 Apr; 111(4):1124-1131. PubMed ID: 32058620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
    Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
    Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.
    Kawano K; Tsuda N; Waki K; Matsueda S; Hata Y; Ushijima K; Itoh K; Yamada A; Kamura T
    Cancer Sci; 2015 Sep; 106(9):1111-7. PubMed ID: 26122553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.
    Obara W; Karashima T; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Inoue K; Katagiri T; Shuin T; Nakamura Y; Fujioka T
    Cancer Immunol Immunother; 2017 Jan; 66(1):17-24. PubMed ID: 27757561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.
    Berinstein NL; Karkada M; Morse MA; Nemunaitis JJ; Chatta G; Kaufman H; Odunsi K; Nigam R; Sammatur L; MacDonald LD; Weir GM; Stanford MM; Mansour M
    J Transl Med; 2012 Aug; 10():156. PubMed ID: 22862954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
    Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Kloor M; Prigge ES; Sauer M; Al-Batran SE; Kaufmann AM; Schneider A; Jäger E; von Knebel Doeberitz M
    Cancer; 2016 May; 122(9):1425-33. PubMed ID: 26949913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
    Noguchi M; Matsumoto K; Uemura H; Arai G; Eto M; Naito S; Ohyama C; Nasu Y; Tanaka M; Moriya F; Suekane S; Matsueda S; Komatsu N; Sasada T; Yamada A; Kakuma T; Itoh K
    Clin Cancer Res; 2016 Jan; 22(1):54-60. PubMed ID: 26581246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.
    Antonilli M; Rahimi H; Visconti V; Napoletano C; Ruscito I; Zizzari IG; Caponnetto S; Barchiesi G; Iadarola R; Pierelli L; Rughetti A; Bellati F; Panici PB; Nuti M
    Int J Oncol; 2016 Apr; 48(4):1369-78. PubMed ID: 26892612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer.
    Toh U; Sakurai S; Saku S; Takao Y; Okabe M; Iwakuma N; Shichijo S; Yamada A; Itoh K; Akagi Y
    Cancer Sci; 2020 Aug; 111(8):2760-2769. PubMed ID: 32495455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
    Benavides LC; Sears AK; Gates JD; Clifton GT; Clive KS; Carmichael MG; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
    Expert Rev Vaccines; 2011 Feb; 10(2):201-10. PubMed ID: 21332269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma.
    Amato RJ; Shetty A; Lu Y; Ellis R; Low PS
    J Immunother; 2013 May; 36(4):268-75. PubMed ID: 23603861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
    J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
    Leffers N; Lambeck AJ; Gooden MJ; Hoogeboom BN; Wolf R; Hamming IE; Hepkema BG; Willemse PH; Molmans BH; Hollema H; Drijfhout JW; Sluiter WJ; Valentijn AR; Fathers LM; Oostendorp J; van der Zee AG; Melief CJ; van der Burg SH; Daemen T; Nijman HW
    Int J Cancer; 2009 Nov; 125(9):2104-13. PubMed ID: 19621448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.